Hypera (HYPE3) Q2 2024 earnings summary

Executive summary

• Sell-out increased 6.3% year-over-year in Q2 2024, driven by chronic and preventive treatments, while respiratory, pain, and influenza categories declined due to high temperatures from El Niño and market mix.

• Net revenue reached R$2,188.9 million in Q2 2024, down 1.9% year-over-year, reflecting a strong prior-year comparison and higher promotional discounts.

• Operating cash flow hit a record R$624.2 million, up 8.0% year-over-year, aided by inventory reduction.

• Significant investments in R&D (7.2% of net revenue), innovation, and production capacity, with a robust pipeline of 500+ products planned.

• Interest on Equity of R$184.9 million (R$0.29/share) approved in Q2 2024.

Financial highlights

• Gross margin was 60.9% in Q2 2024, down 2.3 p.p. year-over-year due to product mix and higher discounts.

• EBITDA from continuing operations was R$755.1 million (margin 34.5%), down 4.5% year-over-year.

• Net income from continuing operations was R$491.8 million, down 2.5% year-over-year, with margin stable at 22.5%.

• Free cash flow reached R$458.9 million, up R$113.8 million from Q2 2023.

• Net debt post-hedge at quarter-end was R$7,260.3 million, or 2.4x expected 2024 EBITDA.

Outlook and guidance

• 1H24 results represent 47% of full-year revenue and EBITDA guidance, and 48% of net income guidance.

• Management maintains 2024 financial projections, targeting R$8.6 billion in revenue and R$1.85 billion in net profit.

• Chronic and preventive treatments expected to drive above-market growth, supported by a strong innovation pipeline.

• Focus remains on reducing inventories to drive operating and free cash flow growth.

• July 2024 showed market growth of 10% in influenza-related drugs, supporting positive H2 expectations.